Thymic cytotoxic T lymphocytes are primed in vivo to minor histocompatibility antigens by unknown
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The thymus has  been recognized as a  primary site for T  cell differentiation 
since the mid-1960s (1, 2). Despite many elegant experiments, attempts to define 
the relationship between organ morphology, cell kinetics, and cell function have 
been hindered by the complexity of thymic architecture and the dynamics of cell 
traffic  within  this  organ,  as  well  as  the  absence  of well-defined  stages  in  the 
pathway  of T  cell  differentiation.  For  example,  even  the  classical  division  of 
thymocytes  into  cortical  and  medullary  cells  is  a  controversial  issue.  Which 
compartments  immunocompetent  thymocytes reside  in,  whether  a  precursor- 
product relationship exists between cortical and  medullary thymocytes, and in 
what  way  these  populations  contribute  to  the  peripheral  pool  of functionally 
mature,  recent thymic migrants are subjects of intense debate (reviewed in  3). 
In this paper, we offer evidence that questions two long-standing tenets of thymic 
physiology, that thymocytes are shielded from extrinsic antigen (4) and that the 
cell traffic within the thymus is unidirectional, moving from intrinsic stem cells 
or from bone marrow-derived stem  cells to the  thymus and  to the  periphery, 
never the reverse (5). In experiments described below, we show that thymocytes 
can be primed by intraperitoneal injection of cells bearing foreign minor histo- 
compatibility (minor H) antigens, and that functional, antigen-reactive peripheral 
T  cells can enter the thymus. 
Materials  and  Methods 
Animals.  C57BL/10nSn (B10, H-2  b) and B10.D2nSn (B10.D2, H-2  d) mice were ob- 
tained  from The Jackson  Laboratory, Bar  Harbor,  ME.  Lewis rats  and  the congenic 
mouse strains  BALB/c (H-2d),  BALB.B (C.B,  H-2b),  BALB.K (C.K,  H-2k),  C57BL/Ka 
(Thy-l.2) [BL(1.2), H-2b], and C57BL/Ka (Thy-l.1) [BL(1.1)] mice were obtained from 
our inbred colony at Stanford University. Mice of at least 6 wk of age were used in all 
studies. 
Reagents.  Rabbit  anti-mouse  thymocyte serum  (ATS) t  was  purchased  from  M.  A. 
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Bioproducts, Walkersville, MD.  Monoclonal anti-Thy-1  reagents include antibodies se- 
creted by the rat-mouse hybridomas T24/31.7 (T24, non-allele-specific anti-Thy-1 [6]), 
30-H12 (anti-Thy-l.2 [7]),  and 53-2.1  (anti-Thy-l.2 [7]).  T24 and 53-2.1  ascites were 
grown in pristane--primed, irradiated. BALB/c mice and gave plateau cytotoxic titers of 3 
x  105 and 3 x  104, respectively. Mouse monoclonal reagents 22.1 (anti-Thy-l.1 [8]),  13- 
4  (anti-Thy-l.2 [8]),  19XE5  (anti-Thy-l.1, kindly provided by R.  C.  Nowinski,  Fred 
Hutchinson Cancer Research Center, Seattle, WA), C3PO (anti-Lyt-l.2 [9]), and AD4-15 
(anti-Lyt-2.2 [10]) were all  used  in  the ascites form. Escherichia coli lipopolysaccharide 
(LPS) (Difco Laboratories, Detroit, MI) and the T  cell mitogens concanavalin A (Con A) 
(Calbiochem-Behring Corp., La Joila, CA) and phytohemagglutin (PHA-P) (Difco Labo- 
ratories)  were  used  with  mouse  cells  at  25,  2,  and  10  #g/ml,  respectively.  Con  A 
supernatant (Con A SN) was harvested from Lewis rat spleen cells cultured for 48 h with 
5 ug]ml Con A. Con A SN was absorbed twice with Sephadex G25 to remove residual 
Con  A  and  titered for interleukin (IL-2) activity on an  IL-2-dependent T  cell clone. 
Wherever possible,  medium  containing Con  A  SN was  supplemented with  50  mM  a- 
methyl-o-mannoside as a  further precaution against  residual Con A.  Where indicated, 
hydrocortisone-2  l-acetate (Sigma Chemical Co., St. Louis, MO) was injected intraperito- 
neally, 5 mg/mouse. 
Treatment with Antibody Plus Complement.  Cells  at  5-20  x  10~/ml  were treated with 
antibody plus a selected rabbit complement (C') in Hanks' balanced salt solution containing 
2 mg]ml bovine serum albumin, as previously described (8). Concentrations of antibody 
used were in excess of those previously determined by titration to mediate plateau levels 
of specific lysis. 
Construction of Thymus-shielded Chimeras.  BL(1.2) mice were anesthetized with tribro- 
moethanol (Aldrich Chemical Co., Milwaukee, WI), taped onto a wooden board, and their 
mid-sternum to head regions covered with a 2-mm lead shield. Mice were then adminis- 
tered 900 rad x irradiation (250 Kvp; Philips Electronic Instruments, Mahweh, NJ.), and 
injected intravenously 4 h later with 1.2 ×  107 Thy-1 congenic BL(1.1) bone marrow cells 
that had been pretreated with a mixture of 22-1 and 19XE5 plus C'. 
Priming for Minor H Antigens.  Mice were primed 9-14 d before sacrifice by injection 
with  1.2  X  107 minor H  different spleen cells.  Spleen cells were either untreated, anti- 
Thy-1 plus C' treated (intraperitoneal injection), or irradiated (intravenous injection). 
Activation and Assay of Cytotoxic T Lymphocytes (CTL).  Bulk mixed lymphocyte cultures 
6  6  6  consisted of 9 X 10  thymocytes or 7 x  10  spleen responder cells and 7 ×  10  1,000 rad- 
irradiated spleen stimulator cells per well in 24-well plates (Costar, Cambridge, MA) in a 
total volume of 2 ml RPMI 1640 medium containing 5% fetal calf serum. Con A SN and 
a-methyl-D-mannoside were added where indicated. CTL activity was measured after 5- 
7 d by culturing serial threefold dilutions of responder cells with 104 5~Cr-labeled target 
cells in 96-well,  round-bottomed microtiter plates (Costar). After 4 h incubation at 37°C, 
the plates were centrifuged, supernatants removed, and the percent specific iysis calculated 
as:  100 x  [(cpm released by effector cells -  cpm released by medium)/(cpm released by 
detergent -  cpm released by medium)]. Effector cells to be typed for Thy-1 expression 
were divided into three aliquots and treated as described above with C' alone, anti-Thy- 
1.1 plus C', or anti-Thy-l.2 plus C'. After treatment and washing, surviving ceils were 
assayed in the usual way for CTL activity. In each case, effector/target ratios were based 
on the number of effector cells recovered from culture on the day of assay. Target cells 
were 2-3 d Con A blasts prepared as previously described (11) and labeled for 1 h with 
sodium 51Cr-chromate (New England Nuclear, Boston, MA). 
For Con A induction of CTL, spleen cells and thymocytes were cultured at 3 x  106/ 
well in 2 ml of medium containing 2 #g/ml Con A with or without Con A SN. The assay 
for polyclonal CTL activity was  performed 3  d  later using 51Cr-labeled  P815  with or 
without 10 #g/ml PHA-P as previously described (12). 
Limiting dilution microcultures consisted of 24 wells each of serial threefold dilutions 
of thymocyte responder cells in round-bottomed microtiter plates. Each well contained 1 
x  106 stimulator spleen cells in a total volume of 200 #! of RPMI  1640 with complete 
supplements,  20%  Con  A  SN  and  50  mM  a-methyl-o-mannoside.  CTL  activity was 438  PRIMING OF THYMIC CYTOTOXIC T  LYMPHOCYTES 
measured 7 d later in a  4-h 5~Cr-release assay by adding 8 ×  103 target cells per well. 
Positive wells were those in which the amount of 5~Cr released exceeded by three standard 
deviations  that  released  in  wells  with  stimulators  alone  (reviewed  in  13). Precursor 
frequencies were calculated both graphically and by weighted mean analysis (14). 
Mitogen-induced [SH]Thymidine Incorporation.  Spleen  cells and  thymocytes were cul- 
tured at  105 cells per well in flat-bottomed, 96-well microtiter plates (Costar) in 200 #l 
medium with 25 #g/ml LPS or 2 #g/ml Con A, with or without Con A SN. As a measure 
of proliferation, the extent of thymidine uptake during a 6-h pulse on day 3 with [SH]- 
thymidine (New England  Nuclear)  was determined using a multiple  automated sample 
harvester (Mini-Mash; M. A. Bioproducts). 
Results 
Minor H-specific CTL Responses Were Generated  from Thymuses and Spleens Only of 
Primed Mice.  Minor H  antigens are cell surface antigens of unknown function, 
an  estimated  40 of which  differ between the  BALB and  C57BL backgrounds 
(15). It has been known for some time that unlike the T  cell responses to various 
haptens  or to  H-2 antigens,  the  generation  of a  measurable  minor  H-specific 
CTL response from spleen cells in bulk culture requires in vivo priming (16, 17). 
The reasons for this requirement  are still  somewhat controversial;  suggestions 
include the increase in the precursor frequency of CTL or helper cells in  the 
memory  response,  the  generation  of suppression  during  a  primary  in  vitro 
response, or some qualitative change in the CTL precursor brought about by in 
vivo priming  (18-20).  We found that  the generation  of minor H-specific CTL 
from bulk cultures of thymocytes had a similar requirement for in vivo exposure 
to minor  H  antigens.  These  findings are depicted in  Fig.  1,  in which in vitro 
stimulated  spleen  cells  and  thymocytes  from  unprimed  BL(1.2)  mice  (H-2  b, 
C57BL minors) generated active anti-H-2 k alloreactive CTL, but were unable to 
become activated to lyse minor H-different C.B (H-2  b, BALB minors) target cells 
(Fig.  1 A and C).  However, good minor  H-specific CTL activity was generated 
both by spleen cells and thymocytes from BL(1.2) mice injected  13 d previously 
with viable C.B spleen cells (Fig.  1 B and D). 
It should be noted that the thymus-derived CTL response was quite vigorous, 
often more active on a per cell basis than the spleen cell response from the same 
animal.  Both  intraperitoneal  and  intravenous  injections of whole spleen  cells, 
anti-Thy-l-treated  spleen cells, and  1,000-rad-irradiated  spleen cells were able 
to prime thymocytes to minor H  antigens. The thymocyte response to minor H 
antigens was generated from animals as early as 4 d and at least as late as  14 d 
after  injection  with  antigen.  The  thymic  response  did  not  always mirror  the 
splenic  response  in  the  extent  of cross-priming  (21)  or  the  extent  of T  cell- 
mediated depletion of the direct primed response (22). Furthermore, the follow- 
ing results show thymus-derived CTL activity to be H-2 restricted: BL(1.2) anti- 
C.B  CTL  did  not  lyse  BALB/c  targets  (which  do  not  bear  the  proper  H-2 
antigens) nor B 10 targets (which do not bear the proper minor antigens) but did 
lyse cells from FI(BALB/c ×  B10) animals. 
It is likely that very small numbers of mature T  cells introduced at the time of 
culture can contribute overwhelmingly to responses measured from thymocyte 
cultures  7  d  after  initiation  (23,  24).  Realizing  this,  we in  all  cases sacrificed 
animals by etherization,  to avoid the introduction  of peripheral  blood iympho- FINK,  BEVAN,  AND  WEISSMAN 
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FIGURE  1.  The generation of minor H-specific CTL from thymus and spleen required in 
vivo priming. Spleen cells and thymocytes were removed from unprimed BL(1.2) mice (A, C) 
or from mice injected intraperitoneally 13 d previously with 1.5 x-10 ~ C.B spleen cells (B, D). 
Thymocytes (with 12%  Con A SN) and spleen cells were cultured either with H-2 allogeneic 
C.K spleen  cells (closed symbols) or  minor  H  different  C.B  spleen  cell stimulators (open 
symbols). CTL activity was measured 5 d later for spleen cell responders (A, B) and on day 7 
for thymocytes (C, and D). Varying numbers of effector cells were assayed for lysis of 51Cr- 
labeled 2-d Con A  blasts of the following types: C.B (O, O), C.K (A, A), and BL(1.2) (El, II). 
Spontaneous release of 5~Cr from targets incubated in the absence of responders was 18-24%. 
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TABLE  I 
Precursor Frequencies of Thymus-derived Alloreactive and Minor 
H-reactive CTL 
Reciprocal precursor frequency 
Responder Status 
AIIoreactive  Minor H-reactive 
Unprimed  32,i00 :t: 2,200  >400,000 
Minor H Primed  27,900 "4- 6,700  46,400:1:12,600 
CTL precursor frequencies were derived by weighted mean analysis of 
data from limiting dilution cultures of BL(1.2) thymocyte responders and 
stimulator spleen cells of BALB/c (alloreactive) or C.B (minor H-reactive) 
origin. Thymocytes were taken  from  unprimed mice or mice that had 
been primed 9-11 d previously with viable C.B spleen cells. Data represent 
the mean +_ standard deviation from three separate experiments. 
cytes, and intraperitoneally injected responder mice  1 h  before sacrifice with 
particulate  India ink,  to  stain  parathymic lymph nodes which could then be 
avoided. Furthermore, limiting dilution analyses revealed that substantial num- 
bers of precursor CTL could contribute to the minor H-specific CTL response 
of primed,  but  not  unprimed,  thymocytes (Table  I).  In  fact,  the  precursor 440  PRIMING  OF  THYMIC  CYTOTOXIC  T  LYMPHOCYTES 
frequency of minor H-specific thymic CTL from primed mice was comparable 
to the frequency of ailoreactive CTL, although somewhat more variable. These 
limiting dilution  data  rule  out  the  possibility  of contamination  of otherwise 
unresponsive thymocytes by small numbers of mature peripheral T  cells, but do 
not eliminate the possibility of contamination on a larger scale. The CTL activity 
we  measured could be  due to cells  from  lymph nodes  that  do  not drain  the 
peritoneum (and therefore would not stain with India ink) or the result of the 
appearance in the thymus of antigen-activated peripheral T  cells, a phenomenon 
that has recently been described for at least some proliferating T  cell lines (25, 
26). In the following several experiments, we attempted to test these possibilities 
by measuring the thymus-derived, minor H-specific CTL response from animals 
whose peripheral immune response has been compromised or eliminated. 
Irradiation of  Peripheral Cells Did Not Prevent Priming of Thymus-derived CTL.  In 
the first set of experiments, BL(1.2) mice were x-irradiated (900-950  rad) with 
a  lead plate shielding the upper chest and head.  On  the same day, mice were 
reconstituted with anti-Thy-l-treated  bone marrow cells from Thy-1  congenic 
BL(1.1) mice. 2 d  later,  mice were injected with minor H  different C.B spleen 
cells, from which viable T  cells had been removed (to allow for unequivocal Thy- 
1 typing at a later stage). On this day, unreconstituted mice were found to retain 
5-7%  of the normal number of viable lymphoid cells in their spleens, lymph 
nodes, and bone marrow (data not shown). On days 11-13 after priming, spleen 
cells and thymocytes were typed for Thy-1  expression, and separately cultured 
with  H-2  aliogeneic (C.K)  or  minor H  different (C.B)  stimulator spleen cells. 
Minor H-specific effector CTL were typed for Thy-1  expression on the day of 
assay.  Representative  thymocyte data  are  depicted  in  Fig.  2.  In  Fig.  2A,  the 
activity of minor H-specific CTL from the thymus of an unirradiated, primed 
BL(1.2) mouse was completely eliminated by pretreatment of effector cells with 
anti-Thy-l.2 plus C', but not by pretreatment with C' alone or with anti-Thy- 
1.1  plus C'.  The latter  treatment did, however,  completely eliminate BL(1.1) 
effector cells (Fig. 2B). Such controls were included in each experiment to insure 
that the anti-Thy-1 pretreatments were both specific and complete. Thymocytes 
from thymus-shielded, irradiated chimeras generated a vigorous minor H-specific 
CTL response after priming with both anti-Thy-1  treated (Fig. 2C) and  1,300 
rad-irradiated (D) C.B spleen cells. In three separate experiments, a  total of 16 
such chimeras were  analyzed  and  all  showed similar  high levels  of minor H- 
specific CTL activity. In each experiment, unprimed, thymus-shielded chimeras 
were included as controls and in each case generated alloreactive CTL but not 
minor  H-specific  CTL  (data  not  shown).  Thy-1  typing  of the  effector  cells 
depicted in C and D reveals that all CTL activity was eliminated by pretreatment 
with anti-Thy-l.2 plus C' and is therefore of host BL(1.2) origin. Furthermore, 
at least some of this thymic activity is resistant to in vivo exposure to cortisone, 
since thymocytes from animals injected with hydrocortisone-acetate 2 d  before 
sacrifice still generated good minor H-specific CTL activity (data not shown). 
The minor H-specific spleen cell responses from such chimeras were somewhat 
variable, lower than those found in unirradiated spleens and in the thymus, but 
never absent (data not shown). Evidence described below has lead us to presume 
that at least some of this primed splenic CTL activity is derived from thymocytes FINK, 
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FIGURE 2.  Thymic minor H-specific CTL  were generated from primed, thymus-shielded 
chimeras. Responding cells were thymocytes from (A) BL(1.2), (B) BL(I.1), and (C and D) 
BL(1.2) mice that were thymus shielded, administered 900 rad, and given 1.2 ×  10  ~ anti-Thy- 
1-treated BL(I. 1) bone marrow intravenously 14 d before sacrifice. Animals were primed to 
minor H antigens by intraperitoneal injection with 1.5 ×  107 anti-Thy-l-treated C.B spleen 
cells (A'C) or intravenously with 1.5 X 107 1,300 rad C.B spleen cells (D). Animals C and D 
were primed 2 d after irradiation. Thymocytes were removed 12 d after priming and placed 
in culture for 7 d with C.B stimulators, in the presence of 12% Con A SN. CTL were treated 
on the day of assay with C' alone (O), with anti-Thy-1.1 plus C' (/X), or with anti-Thy-l.2 plus 
C' (r-l). After this treatment, CTL were assayed for lysis of 2-d Con A blasts from C.B (open 
symbols, 22% spontaneous release) and BL(1.2) (closed symbols, 25% spontaneous release). 
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that have emigrated within the period between priming and sacrifice. However, 
covering the  upper  chest  and  head  shields  not  only the  thymus  but  several 
neighboring lymph nodes. We attempted to minimize the contribution of any 
surviving peripheral T  cells  by intraperitoneally injecting animals 3  d  before 
irradiation  with  300  pl  of commercial  ATS,  a  treatment  that  depletes  the 
periphery of T  cells while leaving the thymus relatively intact (for review, see 
27). Surprisingly, ATS pretreatment did not significantly decrease the magnitude 
of the splenic minor H-specific response at day 12 of priming, but did profoundly 
influence the contribution of donor bone marrow-derived cells to the thymic 
CTL response. In Fig. 3, both splenic (A and C) and thymic (B and D) minor H- 
specific responses, from ATS-pretreated, thymus-shielded, antigen-primed chi- 
meras were typed for Thy-1  expression.  Splenic T  cells  typed on the day of 
culture were all  host-derived (100%  susceptible to anti-Thy-l.2  plus  C') and 
totalled less than half the number of T cells of unirradiated control animals (data 
not shown). Minor H-specific effector CTL from spleens were similarly all host- 
derived (Fig.  3A and  C).  In contrast,  4-6%  thymocytes typed on the day of 
culture from the same ATS-pretreated animals were of BL(1.1) origin; thymo- 
cytes from chimeras that did not receive ATS were 100% host-derived (data not 
shown). Thymic CTL showed a similar degree of chimerism (B and D). In four 442  PRIMING  OF  THYMIC  CYTOTOXIC  T  LYMPHOCYTES 
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FIGURE 3.  Donor bone marrow-derived CTL are generated only from the thymocytes of 
ATS-pretreated, thymus-shielded chimeras. Minor H-specific CTL from spleen cells  (A, C) 
and thymocytes (B, D) from BL(1.2) animals that were injected on day -17 with 300 v.[ ATS, 
7  and on day -14, were thymus shielded, administered 900 rad, and given 1.2 x  10  anti-Thy- 
1-treated BL(1.1) bone marrow cells.  Mice were  given 1.2  X  10  ~ anti-Thy-l-treated C.B 
spleen cells 2  d  later. Spleen cells and thymocytes were  removed  12 d  after priming and 
stimulated in culture with  C.B  spleen cells for  either  5-d (spleen cell  responders) or  7-d 
(thymocyte responders). CTL were treated on the day of assay with C' alone (O), anti-Thy-l.  1 
plus C' (A)  or anti-Thy-l.2 plus C  023). After treatment, responders were assayed on 5~Cr- 
labeled Con A blasts from C.B (open symbols, spontaneous release 19%) and BL(1.2) (closed 
symbols, spontaneous release 25-28%). 
out of five ATS-pretreated animals, a small but significant CTL chimerism was 
detected:  1-8% of the minor H-specific CTL activity was contributed by bone 
marrow-derived BL(1.1) cells. 
We  interpret  these  findings  in  the  following  way:  In  those  animals  whose 
periphery  was depleted of mature  T  cells by ATS and  partial  irradiation,  the 
kinetics of stem cell traffic to the thymus was accelerated. This led to detectable 
numbers  of cells  within  the  thymus  having  recently  arrived  from  the  bone 
marrow.  These  recent  arrivals,  which  had  not  yet  left  the  thymus  for  the 
periphery in detectable numbers,  could contribute to a  primed CTL response. 
The fact that bone marrow-derived CTL were recovered from the thymus and 
not the spleen demonstrates that at least some component of the minor H-specific 
response  in  thymus-shielded  chimeras  was  due  to  thymocytes.  Because  these 
irradiated  and  ATS-treated  hosts  contained  significant  levels  of host-derived 
CTL,  and  because such  cells could  have been  derived from either  thymic  or 
peripheral sites, we cannot estimate the extent to which host extrathymic T  cells 
can also contribute to the thymic CTL activity. 
Minor H-specific CTL  Were Generated from  the Thymus in  the Total  Absence of a 
Peripheral Response.  To analyze further the relative contributions of peripheral FINK,  BEVAN,  AND  WEISSMAN  443 
T  cells and thymocytes to the "thymus-derived" CTL response, we designed a 
protocol  for  preventing  peripheral  activation  to  injected  minor  H  antigens. 
Following the work of Opitz et al. (28) andJ. Watson (personal communication), 
we subjected mice to frequent intraperitoneal injections of high-titered monoclo- 
hal anti-Thy-1  antibodies.  The monoclonal reagents we used are produced by 
rat-mouse  hybridomas T24  (an  IgG2A  non-allele-specific anti-Thy-1  [6]) and 
53-2.1  (an IgG2A anti-Thy-l.2 [7]).  As is documented in Table II, even a single 
injection of T24  ascites profoundly depressed the number of splenic cells ex- 
pressing  T  cell  markers  and  their  ability  to  respond  to  T  cell  mitogens  by 
proliferation or activation of polyclonal CTL.  For example,  S d  after a  single 
injection of 75 #1 T24, <1% of spleen cells were susceptible to lysis by several 
monoclonal anti-Thy-1  antibodies plus C'  (Table  II).  Lyt-1- and Lyt-2-bearing 
cells also decreased to the expected levels (data not shown). The Con A response 
dropped  from  a  stimulation  index  of >400  to  an  index  of  1,  with  the  LPS 
response  relatively  unchanged.  Similarly,  the  Con  A-induced  CTL  response 
dropped dramatically, even with the addition of Con A SN to the cultures (Table 
II). In contrast to the situation in the periphery, the expression in the thymus of 
T  cell  markers  such  as  Lyt-1,  Lyt-2  (data  not  shown),  and  Thy-1,  and  the 
TABLE  II 
In Vivo Treatment with Monoclonal Anti-Thy-1 Antibodies Depleted Periphery but Not Thymus of 
Functional T Cells 
Amount of  Number  Percent of 
antibody  Organ  of cells  untreated 
injected  x  10 -6*  T  cells* 
Mitogenesis  !  Con A-induced CTL 
Percent specific lysis  ! 
-Con A  +Con A  Con A  LPS  SN  SN 
None  Spleen  130  100  409  143  52  43 
Thymus  110  100  40  1  0  44 
25 #l  Spleen  110  82  278  270  30  37 
Thymus  60  100  70  <1  1  49 
75 #i  Spleen  90  0  1  90  0  14 
Thymus  90  100  54  <1  0  40 
225 #1  Spleen  80  1  1  44  0  8 
Thymus  60  I00  84  <1  0  42 
B 10 mice were injected intraperitoneally with the indicated amount of T24 ascites. Spleens and 
thymuses were removed S d  later, typed with antibody plus C' for T  cell markers, cultured with 
the indicated mitogens and measured for proliferation on day 3, or cultured with Con A for $ d 
and measured for polyclonal CTL activity in the presence of PHA. Data are from a pool of two to 
three mice per group. 
* Total number of cells per donor organ. 
* Percent  of cells specifically lysed by  three  monoclonal anti-Thy-1  reagents  in  treated  animals 
relative to the percent of cells lysed in uninjected control animals.  In control animals,  40%  of 
spleen cells were specifically lysed by anti-Thy-l  plus C' (using the percent of cells lysed by anti- 
H-2 antibodies as 100%). 
Figures represent stimulation indexes calculated as: (cpm incorporated with mitogen)/(cpm incor- 
porated with medium). 
I Percent specific lysis at an effector/target ratio of 20:1, calculated from a full titration of responders 
against a constant number of target cells. Cells were cultured with and without 4% Con A SN. 444  PRIMING OF THYMIC CYTOTOXIC T  LYMPHOCYTES 
functional capacity of thymocytes from treated animals, remained intact. In fact, 
like the increase in thymic function reported after ATS treatment (29), the Con 
A (Table II) and PHA responses (data not shown), increased in treated animals. 
This profound depletion of T  cell function in the periphery was maintained 
for at least  10 d  with several injections of T24 and 53-2.1  ascites (Table III). 
BALB/c mice were injected with 200/A of T24, primed to minor H antigens the 
following day with  irradiated  or anti-Thy-l-treated B10.D2  spleen cells, and 
injected with T24 plus 53-2.1  the day after priming. Mice were either rested or 
injected every other day with anti-Thy-1 antibodies and sacrificed on day 9 or 
10 after priming.  Spleen cells and thymocytes were then typed with anti-H-2, 
anti-Thy-1, and anti-Lyt reagents,  or put  into  culture with  H-2  allogeneic or 
minor H  different spleen cells. We attempted to avoid as much as possible the 
problems inherent in comparing thymic cell responses that peak at day 7  and 
which require the addition of factors derived from Con A  SN with spleen cell 
responses, which peak at day 5 and do not require Con A SN. In each experiment 
summarized in Table III, we cultured spleen cells both with and without Con A 
SN and assayed both thymic and splenic CTL responses on day 6 in experiments 
2 and 3. 
As  illustrated  in  Table  III,  the  minor  H  CTL  response  required  in  vivo 
priming, even with thymocytes taken from anti-Thy-l-treated mice (experiment 
3), which functionally may be more competent than cells from untreated animals 
(Table II and reference 29). In all  10 of the primed anti-Thy-l-treated animals 
tested in experiments 1 and 2  (7 of which are illustrated in Table III), spleen 
cells generated no minor H-specific and only low anti-H-2 CTL activity. In data 
not shown, typing for the expression of T  cell markers identified from 0  to a 
maximum of 5% of T  cells in these spleen cell populations,  in contrast to 34- 
45% in the spleens of control mice typed on the same days. These data indicate 
that no surviving peripheral T  cells were activated by the introduction of minor 
H antigens, even in animals that only received two anti-Thy-1 injections, the day 
before and the day after priming. In contrast, thymocytes in 8 of these 10 mice 
generated from low to moderately high levels of minor H-specific CTL activity, 
activity that is clearly not the result of peripheral cell influx. 
We recovered from the spleens of all four of the animals analyzed in experi- 
ment 3 (three of which are shown in Table III) some memory minor H-specific 
CTL activity, detectable only after culture in 6% Con A SN. CTL memory cells 
primed in  the thymus may enter the peripheral pool  during the  3-d interval 
between the  last  Thy-1  injection and  the day of culture,  but  not during the 
shorter intervals in experiments 1 and 2 (Table III). 
Peripheral T  Cells Could Contribute to the  Thymic CTL Response.  The previous 
experiments indicate that a thymic minor H response could occur in the complete 
absence  of a  peripheral  response,  and  that  at  least  a  portion  of the  thymic 
response derived from cells that recently arrived from the bone marrow and had 
yet to  seed  the  periphery.  The  following experiment tests  whether antigen- 
activated peripheral cells can contribute to the thymic CTL response. BL(1.2) 
mice were injected with  minor H  different C.B  spleen cells and with various 
numbers of nonimmune or immune lymph node cells from congenic BL(1.1) 
donors. Lymph node cells were used because they are relatively devoid of thymus- FINK,  BEVAN,  AND  WEISSMAN  445 
TABLE  III 
Minor H-specific CTL Response from Thymocytes in the Absence of a Peripheral Response 
Percent specific lysis* 
Number of antibody  Spleen -  Con A  Spleen  Thymus + Con A 
injections  Priming protocol  SN  + COnsN A  SN 
Ailo-  Minor H  Minor H  Allo-  Minor H 
reactive  reactive  reactive  reactive  reactive 
Experiment 1 
None  None  68  -8  -5  58  -6 
None  Anti-Thy-1 spleen  76  50  62  78  74 
5  Anti-Thy-1 spleen  12  -2  -3  ND  32 
5  Anti-Thy-1 spleen  8  -2  -1  ND  45 
5  Anti-Thy-1 spleen  26  -1  -1  ND  20 
Experiment 2 
None  None  66  - 1  2  78  -2 
None  Anti-Thy-1 spleen  74  52  59  82  64 
2  Anti-Thy-1 spleen  6  -6  -7  84  47 
5  Anti-Thy-1 spleen  1  -7  -3  85  33 
5  Anti-Thy-1 spleen  5  -5  -3  75  42 
5  Anti-Thy-  1 spleen  -1  -4  -5  73  45 
Experiment 3 
5  None  ND  ND  ND  50  2 
None  1,000 rad spleen  45  48  41  84  49 
2  1,000 rad spleen  4  0  16  82  43 
5  1,000 rad spleen  6  1  23  82  54 
5  1,000 rad spleen  3  3  9  81  38 
BALB/c mice were injected intraperitoneally every other day for the indicated number of times 
with 200 tzl of T24 or 200 tA each of T24 and 53-2.1  ascites. Mice were primed 1 d after the first 
injection with 1.2 ×  l0  T B10.D2 spleen cells that had been administered 1,000  rad or pretreated 
with anti-Thy-I plus C'. Responder cells were cultured either with B 10 or with B 10.D2 stimulator 
cells. In experiment 1, animals were sacrificed 9 d after priming and 1 d after the last injection. 
Spleen cells were cultured 5 d with or without 2% Con A SN and thymocytes for 7 d with 10% 
Con A SN. In experiment 2, cells were removed 2 d after the last injection on day 9 of priming, 
and 3 d after the last injection on day 10 of priming in experiment 3. In experiments 2 and 3, 
spleen cells were cultured with or without 6% Con A SN, and thymocytes with  12% Con A SN, 
both for 6 d. Data are tabulated from individual mice. 
* Percent specific lysis at an effector/target ratio of 20:1  on BI0  (alloreactive CTL) or B10.D2 
(minor H-specific CTL) Con A blasts. Spontaneous release in all experiments was 10-29%, with no 
detectable lysis of syngeneic targets in any experiment. 
homing  stem  cells  (30).  Animals  were  sacrificed  12  d  later  and  the  relative 
contribution  of host and donor  cells to the memory  CTL  response determined. 
Representative  results  are  summarized  in  Table  IV.  As  expected,  the  donor 
contribution  to  the  splenic minor  H-specific CTL  response  depended  both  on 
the number  of cells injected and on the immune  status of the donor  mouse.  Of 
the five mice injected with  unprimed  lymph node cells, the donor  contribution 
in the  spleen varied from  0  to 8%,  depending  on the  dose of injected cells. Of 
the  10 recipients of previously primed  lymph node cells, the donor  contribution 
in the spleen varied from 5  to 60%  (Table IV and data not shown). Surprisingly, 
the thymus showed the same pattern  of donor  contribution, from 0  to  1% after 446  PRIMING OF  THYMIC CYTOTOXIC T  LYMPHOCYTES 
TABLE  IV 
Adoptively Transferred, Minor H-primed Peripheral T Cells Can Contribute to the Thymic CTL 
Response 
BL(1.2) lymph node cells 
transferred  Recipient 
Percent specific  Percent anti-Thy- 1.1 
lysis*  resistant* 
Spleen  Thymus  Spleen  Thymus 
None  BL(1.2)  53  74  100  100 
None  BL(1.1)  65  75  0  0 
4 x  107 unprimed  BL(1.1)  58  74  <1  <1 
4 x  107 unprimed  BL(1.1)  50  73  0  <1 
6 × 107 unprimed  BL(I.1)  50  52  3  1 
6 X  l0 T  unprimed  BL(1.1)  57  47  4  1 
4 x  107 primed  BL(1.1)  54  71  8  5 
4 x  107 primed  BL(I.1)  56  78  6  6 
4 × 107 primed  BL(I.1)  58  66  5  40 
4 × 107 primed  BL(1.1)  53  75  14  13 
4 X 107 primed  BL(1.1)  57  72  8  7 
6 x  l0  T  primed  BL(1.1)  57  59  60  60 
6 × 107 primed  BL(I.1)  48  45  50  12 
BL(1.1) mice were injected intraperitoneally  with 1.5 x  107 anti-Thy-l-treated C.B spleen cells 
and intravenously with lymph node cells from BL(1.2) donors that were either unprimed or injected 
4 wk previously with C.B spleen cells. Animals were sacrificed 12 d later and responding  cells 
cultured  for 5 d (spleen cells) or 7 d (thymocytes, plus 12% Con A SN) with C.B stimulators. 
Responding cells were treated on the day of assay with C' alone, anti-Thy-1.1 plus C', or anti-Thy- 
1.2 plus C', and then assayed for CTL activity on 2-d Con A blasts. Spontaneous release was 15- 
23%, with no detectable lysis of syngeneic target cells. 
* Percent  specific lysis of C.B targets  at an effector/target ratio of 20:1,  calculated from a full 
titration of responders against a constant number of target cells. 
A measure of the percent of the minor H-specific response mediated by donor cells, calculated 
from the percent of C.B-specific cytotoxicity that remained after treatment of effector cells with 
anti-Thy-l.1 plus C'. 
the injection of unprimed cells and from 5 to 60% after the injection of previously 
primed lymph node cells.  This relationship  to the  immune status of the  donor 
animal makes it unlikely that we were detecting CTL newly differentiated within 
the thymus from the small number of stem cells in the injected lymph node cells. 
It should be stressed again that thymuses were removed in all cases in the absence 
of contamination by peripheral blood and after intraperitoneal injection of India 
ink to exclude the parathymic nodes. The CTL activity from the thymus did not 
always mirror the peripheral response, as seen in both the third and last recipients 
of primed cells listed in Table IV. These surprising results indicate that antigen- 
activated,  mature,  peripheral  CTL  can enter the thymus and contribute  to the 
thymic memory CTL response (25). 
Discussion 
Our  experiments  show  that  the  generation  of measurable  minor  H-specific 
CTL responses from thymocytes require in vivo priming. We detected at least a 
ninefold increase in the number of thymic CTL precursors from primed relative 
to  unprimed  donors,  in  conditions  of excess  helper  factors  (Table  I).  These 
results strongly suggest that the CTL precursors themselves must be activated in 
vivo, and  that  the  priming effect is not  solely at  the  level of helper  cells.  The FINK,  BEVAN,  AND  WEISSMAN  447 
linearity of our limiting dilution data indicate that the CTL precursor is the only 
limiting cell, and is not affected by a  titratable number of suppressor cells, in 
contrast to the situation described for spleen cells (20). 
We  have presented  evidence suggesting  that  thymocytes, including recent 
immigrants from the bone marrow, are primed in situ, and that mature lymph 
node-derived peripheral  T  cells activated to antigen also lodge in the thymus 
and contribute to the thymic CTL response. Experiments depicted in Table III 
indicate that a  minor H-specific thymic CTL response can be generated from 
primed mice in  the complete absence of a  concomitant splenic response.  The 
thymic CTL response is therefore not solely due to contamination by recirculat- 
ing peripheral T  cells. The fact that mature peripheral T  cells can contribute to 
the thymic CTL response is illustrated in Table  IV, where up to 60%  of the 
thymic response to minor H antigens in bulk culture can be ascribed to previously 
primed adoptively transferred lymph node cells. These data do not allow the 
determination of the fraction of CTL that are donor derived. The appearance 
of mature T  cells in the thymus has been described in the rat by Naparstek and 
colleagues (25, 26). In these experiments, T  cell lines that proliferate in response 
to myelin basic protein were shown to lodge in the thymus in small numbers only 
after recent antigen activation in vitro (25). The fact that >99% of these injected 
cells end up in organs other than the thymus accords with data showing that 
detectable numbers of mature T  cells do not specifically home to the thymus 
within 24 h after intravenous injection (5, 30). The significance of these experi- 
ments lies in the fact that the few cells that enter the thymus remain functional 
for up to 2 mo (25). It is unknown by what means and with what kinetics antigen- 
activated peripheral T  cells enter the thymus or where they reside, facts that 
may in the future provide clues as to the possible intrathymic function of these 
persisting, mature T  cells. 
We know little about the properties of the CTL in the thymus that respond to 
minor H  antigens. At least a  fraction of the minor H-specific CTL response is 
resistant to the injection of cortisone 2 d before culture (see Results). However, 
this finding has little bearing on the sensitivity of responding cells at the time of 
antigen injection, for the necessary 10 d interval between priming and culture is 
more than enough time for cortisone-sensitive cells to become cortisone resistant 
(31). It appears that even in the presence of an excess of helper factors, cells of 
minority ("medullary") phenotype comprise the vast majority of thymocytes that 
proliferate or differentiate to CTL in the presence of Con A (23, 32) or allogeneic 
stimulator cells (24).  It must be stressed that this minority phenotype has been 
defined by parameters other than intrathymic location. It is thus possible that 
small numbers of cells of this phenotype reside in the cortex (33), and that it is 
these cells which are the functionally mature thymocytes destined to seed the 
peripheral lymphoid organs.  We  have  shown here that  at  least a  part  of the 
thymic minor H response is due to cells that have recently (within 2 d of antigen 
injection) arrived from the bone marrow (Fig. 3). Furthermore, we suspect that 
some thymic-derived, minor H-specific CTL are being exported to the periphery, 
as  suggested  by  the  difference in  the  magnitude  of the  splenic  response  in 
experiments 2 and 3, Table III. From all of these observations we surmise that 
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cells, at  least a  fraction of which turn over more rapidly than  the long-lived, 
cortisone-resistant cell subpopulation previously described (34). Anything more 
than conjecture must await a  means of identifying these CTL precursors inde- 
pendent of their response, perhaps by their in vivo association with nonlymphoid 
cells of the thymus (35) or by expression of a particular cell marker (36). 
It must be pointed out that it is still  formally possible that pre-T cells meet 
antigen in the periphery, either in the bone marrow or en route to the thymus. 
We feel that the consistently vigorous, host-derived CTL response from thymus- 
shielded chimeras (Fig.  2),  even those pretreated with ATS (Fig.  3), favors the 
interpretation  that  resident  thymocytes and  not  only  immigrating pre-T  or 
peripheral T cells contribute to this activity. Furthermore, priming of pre-T cells 
would require the expression by these cells of receptors that can bind both to 
the self H-2  antigens and  to a  diverse number of foreign minor  H  antigens. 
Given the proposed roles of the thymus in receptor selection (reviewed in  37) 
and the exceedingly small number of pre-T cells that can seed the thymus of an 
irradiated animal (38, 39; and S. Ezine, R. Rouse, and I. Weissman, manuscript 
submitted), we find the proposed expression by pre-T cells of receptors that bind 
to antigen in an H-2-restricted fashion highly unlikely. Most of the experiments 
interpreted as  demonstrations of pre-T  cell  receptor expression  can  also  be 
interpreted as low level expression of "environmental" antigen within the thymus 
(40, 41). Due to the lack of reliable anti-minor H  antibodies for typing, a direct 
test  for  the  presence  of minor  H  antigens  in  the  thymus  would  require  a 
functional assay. Related experiments have shown that purified thymic dendritic 
cells from animals injected intravenously with either soluble protein antigens or 
semiallogeneic spleen cells can present antigen to T  cell clones in vitro (B.  A. 
Kyewski and H. S. Kaplan, manuscript submitted). Dendritic cells are found at 
the corticomedullary junction or in  the medulla (42,  43) and therefore these 
recent findings are not contradictory to the experiments of Raviola and Karnof- 
sky (44), demonstrating the exclusion of foreign protein antigens from the cortex 
but not the medulla. 
If as we suspect, antigens do enter the thymus, it is unknown how and in what 
form this entry is allowed. We have found that priming for minor H  antigens 
requires neither the injection of viable cells, T  cells, nor cell preparations with 
efficient thymus-homing ability. We predict the entry into the thymus of antigen- 
presenting cells or their precursors in  the foreign spleen cell preparation,  or 
antigens processed by host antigen-presenting cells, perhaps in the normal course 
of the  turnover  of thymic  antigen-presenting  cells  (35,  45).  These  foreign 
antigens  must  be  compartmentalized and  not  allowed to  freely interact with 
thymocytes in all stages of differentiation. To maintain the distinction between 
self and nonself, thymocytes in a  tolerizable state must be secluded from this 
pool of foreign antigens (4, 46). 
In  conclusion,  injected  minor  H  antigen-bearing  cells  prime  thymic  CTL 
precursors specifically reactive to these antigens. Under differing experimental 
conditions,  these primed thymic CTL  were shown  to  be derived from three 
independent  sources:  pre-T  cells,  intrathymic  lymphocytes, and  extrathymic 
mature T  cells. The experiments herein reported do not quantify the relative 
contributions of these three populations under physiologic conditions, an issue FINK, BEVAN, AND WEISSMAN  449 
that is not currently susceptible to experimental investigation. Nevertheless, we 
believe that each population experimentally revealed may contribute, perhaps in 
strikingly distinct ways, to the physiological response of the thymus to self and 
nonself antigens. Whether these responses control intrathymic maturation, ex- 
trathymic immunity, or both, awaits suitable model systems. 
Summary 
Potent cytotoxic T  lymphocyte (CTL) activity can be derived from cultures of 
thymocyte responders and minor H  different spleen cell stimuiators.  As is the 
case  for  the  spleen  cell  response  previously  reported,  this  cytotoxic activity 
requires in vivo priming. We performed several experiments designed to deter- 
mine whether the in vivo priming effect is due to the in situ priming of thymocyte 
CTL  precursors,  to  contamination  of thymus cell  preparations  with  cells  of 
neighboring lymph nodes, or to the appearance in the thymus of antigen-reactive 
peripheral T  cells. We show by depletion of peripheral cells with antilymphocyte 
serum and part body irradiation that recent thymic immigrants derived from the 
bone  marrow  contribute  to  the  primed  thymic  respnse.  Thymic CTL  were 
primed in animals in which peripheral T  cell responses were completely elimi- 
nated  by  repeated  treatment  in  vivo  with  monoclonal  anti-Thy-1  reagents. 
Primed, antigen-activated lymph node cells were also demonstrated to contribute 
to the thymus-derived CTL response. Thus, the minor H-specific thymic CTL 
response  is  due  both  to  in  situ  priming  and  the  immigration  of activated 
peripheral  T  cells.  We  discuss  the possible  significance for models of T  cell 
differentiation of the presence within the thymus of antigen and antigen-reactive 
mature T  cells. 
We are grateful for stimulating discussions with our colleagues, particularly B. A. Kyewski, 
and the expertise of L. Jerabek, L. Hu, and J. McLain. 
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